San Francisco - Individualization of drug therapy is becoming a reality with the recognition that the response to drugs varies as a result of sequence variants in genes encoding drug-metabolizing enzymes, drug transporters, or drug targets.
FDA Approves Lebrikizumab-lbkz for Moderate to Severe Atopic Dermatitis
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
April Armstrong, MD, MPH, Shares Insights on the NPF's Psoriasis Health Indicator Report
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Definitions and Diagnostic Criteria of Generalized Pustular Psoriasis Require Continuity, Accuracy, Researchers Report
Comparing Devices to Assess Facial Pigmentary and Inflammatory Conditions